This very exciting trial, which we have supported from the beginning, will have two new centres in the UK in early 2020 located in Torbay and Edinburgh. The existing centres, which are recruiting patients, are shown on this page of our website (which links to more details of the trial).

The CUPSICO trial is a Phase II genomic profiling study to evaluate the efficacy and safety of molecularly-guided therapies versus chemotherapy in CUP patients who have achieved disease control after 3 cycles of platinum-based induction chemotherapy.

The study currently involves 32 countries around the world including the UK and the Republic of Ireland, with a target of 790 patients to be enrolled globally.

< Back to articles